Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gijs Zom"'
Autor:
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs Zom, Renoud Marijnissen, Gerwin Sandker, Sandra Heskamp, Sjoerd van den Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell infiltrate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53efff7a4d0e88f729b064b35ec9c84b
https://doi.org/10.21203/rs.3.rs-2470572/v1
https://doi.org/10.21203/rs.3.rs-2470572/v1
Autor:
Middelburg, Jim1 (AUTHOR) j.middelburg@lumc.nl, Kemper, Kristel2 (AUTHOR) kke@genmab.com, Engelberts, Patrick2 (AUTHOR) pen@genmab.com, Labrijn, Aran F.2 (AUTHOR) ala@genmab.com, Schuurman, Janine2 (AUTHOR) jsc@genmab.com, van Hall, Thorbald1 (AUTHOR) T.van_Hall@lumc.nl
Publikováno v:
Cancers. Jan2021, Vol. 13 Issue 2, p287-287. 1p.